Story perspectives

Atyr Pharma Stock Crashes 82% After Drug Trial Failure

9/15/2025

37 4

Summary

Story summary

Atyr Pharma's stock (ATYR) plummeted 82% after its drug efzofitimod failed to meet primary goals in a late-stage pulmonary sarcoidosis study involving 268 patients.
The trial aimed to reduce steroid use, showing a non-significant decrease from 3.52 mg (placebo) to 2.79 mg (efzofitimod).
The company plans to consult with the FDA regarding future steps.
Some analysts noted potential benefits, with a few patients achieving complete steroid withdrawal.
Atyr's stock rose 66.6% in 2025, indicating prior investor interest.

1 of 1

Story summary

Atyr Pharma's stock (ATYR) plummeted 82% after its drug efzofitimod failed to meet primary goals in a late-stage pulmonary sarcoidosis study involving 268 patients.
The trial aimed to reduce steroid use, showing a non-significant decrease from 3.52 mg (placebo) to 2.79 mg (efzofitimod).
The company plans to consult with the FDA regarding future steps.
Some analysts noted potential benefits, with a few patients achieving complete steroid withdrawal.
Atyr's stock rose 66.6% in 2025, indicating prior investor interest.